Client politics a test of vendor diplomacy skills

Pharma clinical development and product commercialization teams should align around bringing a new drug to market. Yet too often, internal politics interfere with clinical trials, labeling and publication strategy decisions.

“The challenge involves getting marketing and clinical together early to hash out these things,” said Debbie Kossman, PhD, SVP, healthcare practice, National Analysts Worldwide.

When working with clients, pharmaceutical marketing research vendors often need to be as much therapist as industry expert, she said. Kossman presented as a success story her experience working with Amgen on the clinical trial design of the biotech's Kepivance (palifermin), a biologic for treating oral mucositis approved in 2004.

NAW provided an overview of views and treatment practices for mucositis as well as an evaluation of palifermin's therapeutic value. Meanwhile, clinical development and marketing articulated questions for KOL interviews.

Amgen's internal culture was not so political. “Today we have an integrated, cross-functional team that really monitors an asset all through the development process,” said John Meyers, Amgen executive director, business analysis and information.

However, not all companies are as harmonious. Senior management would be well-served to work out the development-commercial divide.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.